ReviewXenotransplantation
Xenotransplantation Literature Update: January-June 2026.
Review in Xenotransplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the first half of 2026, xenotransplantation advanced through refinement rather than dramatic new clinical milestones. Clinical studies described graft physiology, immune infiltration, complement activation, coagulation incompatibility, and early function in living recipients, decedent models, and clinical islet xenotransplantation, including the first orthotopic multi-organ decedent xenotransplantation model. Additional preclinical studies in pigs and nonhuman primates on kidney, heart, islets, and blood product models used more advanced engineering of donor organs, including up to ten genetic edits. They identified persistent issues such as thrombotic microangiopathy, renin-angiotensin-aldosterone system dysregulation, and hemolysis-induced ferroptosis. Translational advances in xenotransplantation included the Banff guidelines for xenograft pathology, detection of cell-free DNA derived from the donor, complement, better histocompatibility tests, improved immunosuppressive approaches, and biosafety considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.